First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M.

臺大醫院;臺大醫院-腫瘤醫學部;臺大醫院-醫學研究部;臺大醫學院-腫瘤醫學研究所;臺大醫學院-臨床醫學研究所;Tan, Daniel Shao-WengDaniel Shao-WengTanSeto, TakashiTakashiSetoLeighl, Natasha B.Natasha B.LeighlRiely, Gregory J.Gregory J.RielySequist, Lecia V.Lecia V.SequistFelip, EnriquetaEnriquetaFelipWolf, JuergenJuergenWolfYang, James Chih-HsinJames Chih-HsinYangMatushansky, IgorIgorMatushanskyYu, XiaoluXiaoluYuSchmitz, Shu-Fang HsuShu-Fang HsuSchmitzCui, XiaomingXiaomingCuiKim, Dong-WanDong-WanKim2017-06-222018-07-092017-06-222018-07-092015http://ntur.lib.ntu.edu.tw//handle/246246/279801[SDGs]SDG3First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M.